Patents by Inventor Robert William Siegel, II

Robert William Siegel, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXYNTOMODULIN BINDING MOLECULES, AND USES THEREOF
    Publication number: 20240059770
    Abstract: Provided herein are novel N- and C-terminal oxyntomodulin polypeptide binding molecules, and uses thereof, including a method for quantitating oxyntomodulin.
    Type: Application
    Filed: January 19, 2022
    Publication date: February 22, 2024
    Inventors: Robert John KONRAD, Wenyu MING, Robert William SIEGEL, II, Tara Suzanne UMBERGER
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-19
    Publication number: 20230220062
    Abstract: The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.
    Type: Application
    Filed: January 25, 2023
    Publication date: July 13, 2023
    Inventors: Richard Earl HIGGS, Jr., Robert John KONRAD, Brian Jeffrey NICKOLOFF, Robert William SIEGEL, II
  • Compounds and methods targeting interleukin-19
    Patent number: 11591387
    Abstract: The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: February 28, 2023
    Assignee: Eli Lilly and Company
    Inventors: Richard Earl Higgs, Jr., Robert John Konrad, Brian Jeffrey Nickoloff, Robert William Siegel, II
  • COMPOUNDS AND METHODS TARGETING HUMAN TAU
    Publication number: 20220146535
    Abstract: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine 217 and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 12, 2022
    Inventors: Xiyun CHAI, Jinbiao CHEN, Jeffrey L. Dage, David Albert Driver, Steven Fisher Hinton, Robert William Siegel, II, Peter Edward Vaillancourt
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-19
    Publication number: 20200354444
    Abstract: The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.
    Type: Application
    Filed: June 17, 2020
    Publication date: November 12, 2020
    Inventors: Richard Earl Higgs, JR., Robert John Konrad, Brian Jeffrey Nickoloff, Robert William Siegel, II